Guardian University of the Year 2019; Times and Sunday Times Modern University of the Year 2018; THE 2017 University of the Year; these are just some of the accolades bestowed upon Nottingham Trent University. We are focused on ‘Creating the University of the Future’, transforming the lives of our students and, through them, the world in which we live.
We are doing this through empowering and creating opportunity for all our students and staff so as they may learn, discover, and enrich society locally, nationally, and internationally. Investment in people and facilities is a cornerstone to our success, including over £60 million in teaching and research facilities in the School of Science and Technology since 2016.
We are seeking to appoint a committed and passionate academic with a clear vision and excellent interpersonal skills, as the new Professor of Cancer Genomics in the John Van Geest Cancer Research Centre (JvGCRC). You will develop, lead and inspire research, scholarship and/or practice activity which enhances the profile of JvGCRC and drives our mission to turn discovery into health by accelerating the translation of basic science towards patient tailored therapies. You will undertake personal research in an area relevant to the Centre and be appointable at Professorial level.
The John Van Geest Cancer Research Centre
In 2008, the John and Lucille van Geest Foundation generously endowed Nottingham Trent University with a research grant of £8 million to establish a dedicated cancer research facility. The JvGCRC is a stand-alone purpose-built research facility within the School of Science and Technology (SST), which has an outstanding reputation for teaching and innovation. SST is home to multiple state-of-the-art research facilities, including the newly established £24m Medical Technologies Innovation Facility, and the new £23M Engineering building.
The JvGCRC promotes and prioritises initiatives in personalised cancer medicine using onsite ‘omics’ technologies/facilities (NanoString nCounter and GeoMx Digital Spatial Profiling platforms, Proteomics Suite, high-dimensional flow cytometry, 10X Genomics to perform single-cell RNA sequencing), computational biology/bioinformatics/big data analytics, and interfaces with clinical activities through national and international collaborators.
Our ambitions revolve around 1) understanding tumour-host interactions in a variety of models/conditions (e.g., acute myeloid leukaemia, breast, pancreatic and colon cancer, malignant glioma); 2) developing cancer immunotherapy approaches and anti-tumour vaccines using both in vivo and in vitro onsite pre-clinical facilities; 3) leveraging “big data” to resolve the molecular basis of cancer heterogeneity; 4) deciphering the composition and functional orientation of the tumour microenvironment; 5) discovering biomarkers for clinical use.
The Centre also undertakes commercial work with national and international partners and has generated two impact case studies during the previous REF period.
To download the job description and person specification, please click here.
For more information on JvGCRC, please click here.
NTU prides itself on being an inclusive employer. We value and celebrate equality in opportunities, and we welcome applications from people who reflect the diversity of our communities.
How to apply
Anderson Quigley is acting as an advisor to the University. An executive search process is being carried out by Anderson Quigley in addition to the public advertisement.
Should you wish to discuss the role in strict confidence, please contact our advising consultants at Anderson Quigley:
The closing date for applications is noon on Friday 28 January 2022.
Applications should consist of:
Completed applications should be uploaded at https://andersonquigley.com/candidates/ using the reference AQ1257